{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:54:52Z","timestamp":1776297292592,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jchf.2025.102850","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T20:37:20Z","timestamp":1767645440000},"page":"102850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypotension and the Effects of Finerenone in Heart Failure With Preserved and Mildly Reduced Ejection Fraction"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1120-5461","authenticated-orcid":false,"given":"Pedro","family":"Marques","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana F.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2025.102850_bib1","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/ejhf.3214","article-title":"Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction: a survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.jchf.2025.102850_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102779","article-title":"Finerenone-related risk of hypotension in heart failure with mildly reduced or preserved ejection fraction","volume":"14","author":"Fo\u00e0","year":"2026","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.102850_bib3","first-page":"188","article-title":"Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction","volume":"8","author":"Serenelli","year":"2020","journal-title":"Heart Failure"},{"key":"10.1016\/j.jchf.2025.102850_bib4","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2025.102850_bib5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ejhf.1060","article-title":"Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial","volume":"20","author":"Selvaraj","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.102850_bib6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(16)30075-7","article-title":"PATHWAY-2","volume":"387","author":"Boutari","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2025.102850_bib7","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and its response to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Webb","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jchf.2025.102850_bib8","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/ejhf.3715","article-title":"Profiling hypotension in heart failure based on office, orthostatic and ambulatory blood pressure measurements","volume":"27","author":"Soloveva","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.102850_bib9","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.jacc.2023.03.426","article-title":"Uptitrating treatment after heart failure hospitalization across the spectrum of left ventricular ejection fraction","volume":"81","author":"Pagnesi","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102850_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jacc.2025.05.033","article-title":"Sodium-glucose cotransporter 2 inhibitor with and without an aldosterone antagonist for heart failure with preserved ejection fraction: the SOGALDI-PEF trial","volume":"86","author":"Ferreira","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102850_bib11","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/ejhf.3726","article-title":"Down-titrating diuretics in heart failure","volume":"27","author":"Ferreira","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.102850_bib12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/ejhf.2376","article-title":"Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur J Heart Fail"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925007802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925007802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:15:20Z","timestamp":1776294920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177925007802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2213177925007802"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2025.102850","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypotension and the Effects of Finerenone in Heart Failure With Preserved and Mildly Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2025.102850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2025.102779","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}],"article-number":"102850"}}